Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Impaired neutralisation of SARS-CoV-2 delta variant in vaccinated patients with B cell chronic lymphocytic leukaemia

Fig. 2

SARS-CoV-2 spike-specific antibody responses after vaccination in patients with CLL in relation to stage of disease. A Infographic to show the proportion of patients who develop an antibody response after COVID-19 vaccination in relation to disease stage and management (n = 484). B (i) Proportion of patients on BTKi therapy who develop a positive antibody response by line of therapy (p = 0.07) and (ii) in relation to current or previous BTKi therapy (p = NS). (iii) The proportion of patients with a positive antibody response who had received an anti-CD20 therapy within 12 months or longer (p = 0.008). C (i) Antibody titres in CLL patients who develop an positive antibody response (n = 244). Antibody titres do not vary across the disease course. (Untreated; Treatment planned (TP); Bruton Tyrosine Kinase therapy (BTKi); BCL-2 inhibitor (BCL-2); Previous Chemo-immunotherapy but not on active therapy (pCI). (ii). Antibody titres in relation to ‘time since diagnosis’ in patients who develop an antibody response and are on expectant ‘watch and wait’ management (r =  − 0.25; p = 0.0008). (iii) Antibody titres are broadly maintained at 4 months after vaccination. Serial titres at 5-weeks after first vaccine, 2–3 weeks after second vaccine and 4-months (range 3–8) after second vaccine (n = 56) (p = 0.0006 Wilcoxon paired analysis between 2nd and 3rd bleed time point)

Back to article page